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Abstract
Background: Rift Valley fever (RVF) is an arthropod-borne viral zoonosis. Rift Valley fever virus (RVFV) is an important
biological threat with the potential to spread to new susceptible areas. In addition, it is a potential biowarfare agent.
Methodology/Principal Findings: We developed two potential vaccines, DNA plasmids and alphavirus replicons, expressing
the Gn glycoprotein of RVFV alone or fused to three copies of complement protein, C3d. Each vaccine was administered to
mice in an all DNA, all replicon, or a DNA prime/replicon boost strategy and both the humoral and cellular responses were
assessed. DNA plasmids expressing Gn-C3d and alphavirus replicons expressing Gn elicited high titer neutralizing antibodies
that were similar to titers elicited by the live-attenuated MP12 virus. Mice vaccinated with an inactivated form of MP12 did
elicit high titer antibodies, but these antibodies were unable to neutralize RVFV infection. However, only vaccine strategies
incorporating alphavirus replicons elicited cellular responses to Gn. Both vaccines strategies completely prevented weight
loss and morbidity and protected against lethal RVFV challenge. Passive transfer of antisera from vaccinated mice into naı ¨ve
mice showed that both DNA plasmids expressing Gn-C3d and alphavirus replicons expressing Gn elicited antibodies that
protected mice as well as sera from mice immunized with MP12.
Conclusion/Significance: These results show that both DNA plasmids expressing Gn-C3d and alphavirus replicons
expressing Gn administered alone or in a DNA prime/replicon boost strategy are effective RVFV vaccines. These vaccine
strategies provide safer alternatives to using live-attenuated RVFV vaccines for human use.
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Introduction
Rift Valley fever (RVF) is an arthropod-borne viral zoonosis.
The causative agent Rift Valley fever virus (RVFV) belongs to the
genus Phlebovirus of the family Bunyaviridae and was first discovered
in the Rift Valley of Kenya in 1931 [1]. RVFV infections in
livestock are characterized by an acute hepatitis, abortion and
high mortality rates, especially in new born or young animals.
Human infection with RVFV typically leads to a mild flu-like
febrile illness. However, ,2% of infected individuals have more
severe complications, such as retinal degeneration, fatal hepatitis,
severe encephalitis and hemorrhagic fever [2]. The ability of
RVFV to cross geographic or national boundaries, coupled with
the fact that RVFV replicates in a wide range of mosquito
vectors, have raised concerns that the virus might spread further
into non-endemic regions of the world. Before 1977, RVFV
circulation was not detected beyond the Sub-Saharan countries.
However, since 1997, RVFV outbreaks have occurred in Egypt
[3], Mauritania in 1987 and 1998 [4], Saudi Arabia and Yemen
[5]. In 2006–2007, RVFV outbreaks were recorded in Kenya,
Somalia and Tanzania that resulted in human infections and
deaths [6]. Thus, the ability of RVFV to cause explosive ‘‘virgin
soil’’ outbreaks in previously unaffected regions demonstrates the
need for prophylactic measures for this significant veterinary and
public health threat.
The virus genome is composed of three single-stranded
negative-sense RNA segments. The large (L) segment (,6.4kb)
encodes for the RNA-dependent RNA polymerase [7]. A medium
(M) segment (,3.8kb) encodes for four known proteins in a single
open reading frame (ORF). These include the two structural
glycoproteins, Gn and Gc, and the 14kDa non-structural NSm
protein and the 78kDa NSm-Gn fusion peptide [7,8,9]. The small
(S) segment is ambisense and encodes for the 1.6kDa viral
nucleoprotein (N) in genomic orientation, as well as a non-
structural (NSs) protein in the anti-genomic orientation [7]. The
nonstructural genes (NSs and NSm) function to suppress host
antiviral responses [10,11].
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emerge in new areas through the spread of infected insect vectors
or livestock or though intentional release as a bioterror agent. [12].
Inactivated RVFV vaccine (TSI-GSD-200) have been shown to
elicit protective immunity in humans [13], however multiple
booster vaccinations are required to achieve protective immunity,
and perhaps most importantly, for many individuals, immunity
rapidly wanes in the absence of follow-up booster vaccinations
[13]. A modified live virus vaccine, based upon the Smithburn
strain, is available for livestock in Africa [14], but it can cause
pathology, spontaneous abortions, and teratogenic effects [15,16],
furthermore, animals vaccinated with live attenuated RVFV
strains cannot be differentiated from naturally infected livestock,
which may preclude export of these animals to non-RVFV
endemic areas. One vaccine candidate under evaluation for
human use is MP12, which is a mutagen-attenuated strain of the
Egyptian RVFV isolate, ZH548 [17]. This vaccine was developed
for use in both humans and livestock, with encouraging results in
initial animal trials, but may cause teratology in pregnant animals
[18]. In addition to the adverse effects of the live-attenuated
vaccines, there are considerable safety concerns including
incomplete attenuation, reversion back to virulent form during
the vaccine manufacturing process. Therefore, new approaches
are necessary to develop safe and effective vaccines.
Given limitation of existing RVFV vaccines, there is a need to
explore alternative vaccine approaches. Previous studies have
shown that DNA vaccines can elicit protective anti-RVFV
immunity. Studies from our group and others have demonstrated
that the molecular adjuvant C3d can significantly enhance
antibody responses against DNA vaccine delivered antigens
[19,20,21,22,23,24,25]. C3d adjuvanticity involves C3d binding
to the complement receptor 2 (CR2) that is located on the surface
of follicular dendritic cells (FDC), B cells, and T cells in many
species (For review, see Toapanta and Ross) [26]. C3d stimulates
antigen presentation by FDCs and helps to maintain immunolog-
ical B cell memory. On B cells, C3d interaction with CR2 collects
molecules, such as CD19 and TAPA. CD19 has a long
intracellular tail that triggers a signaling cascade that results in
cell activation and proliferation. Furthermore, simultaneous C3d–
CR2 ligation and surface immunoglobulin (sIg) by antigen,
activates two signaling pathways that cross-talk and synergize to
activate B cells, thereby leading to enhanced antibody secretions
specifically directed to the fused antigen. Therefore, we assessed
whether fusion of murine C3d to the RVFV Gn glycoprotein
would result in enhanced RVFV specific immune responses in the
context of DNA vaccination.
Alphavirus replicon vectors are single hit vectors capable of
eliciting potent systemic and mucosal immune responses against
a wide range of pathogens, including hemorrhagic fever viruses,
such as Lassa and Ebola [27]. Recently, we and others have
demonstrated that alphavirus replicons based upon either VEE
or Sindbis viruses were capable of eliciting protective anti-
RVFV immune responses when the vectors expressed both
RVFV glycoproteins from the RVFV M segment [28,29]
However, there has not been a direct comparison between
DNA and alphavirus-based vectors, or an assessment of whether
combining these vaccine strategies results in enhanced immunity
or qualitative differences in the RVFV specific immune
response. Furthermore, to date, RVFV vaccination studies have
focused on antibody responses, and the ability of different
vaccination strategies to elicit RVFV specific T cell responses
has not been evaluated. Therefore, studies were conducted to
directly compare DNA vaccines expressing either Gn or Gn-
C3d to alphavirus vectors expressing Gn, evaluate whether
combining these vaccines in a DNA prime/replicon boost
strategy provided any advantage over either vaccine on its own,
and to assess the nature of the antibody and T cell response
elicited by each of these vaccine strategies.
Materials and Methods
Plasmid DNA
pTR600, a eukaryotic expression vector, has been described
previously [23]. Briefly, the vector was constructed to contain the
cytomegalovirus immediate-early promoter (CMV-IE) plus intron
A (IA) for initiating transcription of eukaryotic inserts and the
bovine growth hormone polyadenylation signal (BGH poly A) for
termination of transcription. The vector contains the Col E1
origin of replication for prokaryotic replication and the
kanamycin resistance gene (Kan
r) for selection in antibiotic
media.
The gene sequence encoding for the RVFV, isolate ZH548
(Genbank DQ380206), Gn glycoprotein was used to PCR amplify
a soluble form of Gn (Gn) without the transmembrane and
cytoplasmic tail (Fig. 1A). The Gn gene sequence was cloned into
the pTR600 vaccine vector by using unique HindIII and BamHI
restriction endonuclease sites. This Gn segment encoded a region
from amino acids 131 to 557 (427 amino acids) and terminated in
the sequence VAHCP. The vectors expressing Gn fused to three
tandem repeats of the mouse homologue of C3d were cloned in
frame and designated Gn-C3d, similar to constructs previously
described [30]. Linkers composed of two repeats of four glycines
and a serine [(G4S)2] were fused at the junctures of Gn and C3d
and between each C3d repeat. Potential proteolytic cleavage sites
between the junctions of Gn and the junction of C3d were
mutated by ligating BamHI and BglII restriction endonuclease sites
to mutate an Arg codon to a Gly codon [30].
The plasmids were amplified in Escherichia coli DH5a; purified
by using endotoxin-free, anion-exchange resin columns (Qiagen,
Valencia, CA, USA); and stored at 220uC in distilled H2O.
Plasmids were verified by appropriate restriction enzyme digestion
and gel electrophoresis. Purity of DNA preparations was
determined based on the optical density (O.D.) at wavelengths of
260 and 280 nm.
Author Summary
Rift Valley fever virus (RVFV) is an arthropod-borne
phlebovirus associated with abortion storms, neonatal
mortality in livestock and hemorrhagic fever or fatal
encephalitis in a proportion of infected humans. Require-
ment of multiple booster immunizations to maintain the
level of protective immunity with the inactivated vaccines
and the ability of live-attenuated vaccines to cause
detrimental side-effects are major limitations preventing
the widespread use of current vaccines. In this paper, we
describe the use of DNA and alphavirus replicon based
vaccination approaches to elicit a protective immune
response against RVFV. While both vaccines elicited high
titer antibodies, DNA vaccination elicited high titer
neutralizing antibodies, whereas the replicon vaccine
elicited cellular immune responses. Both strategies alone
or in combination elicited immune response that com-
pletely protected against not only mortality, but also
illness. Even though the delivery vectors elicited some
protection on their own, they did not prevent severe
morbidity. These promising vaccines provide an alternative
RVFV vaccine for livestock and humans.
DNA and Alphavirus Replicon Vaccines for RVFV
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A soluble form of RVFV Gn lacking the transmembrane and
cytoplasmic tail (see above) was introduced behind the 26S
subgenomic promoter of the VEE replicon plasmid pVR21 as
outlined in Figure 1B. VEE replicons expressing influenza
hemagglutinin were used as negative controls. VEE replicon
plasmids, as well as capsid and glycoprotein plasmids were
linearized with NotI, replicon and helper transcripts were
generated using mMessage mMachine T7 transcription kits
(Ambion), and transcripts electroporated into BHK-21 cells to
package replicon particles as described previously [31]. Following
packaging, the replicons underwent two rounds of safety testing to
ensure that no detectable replication competent virus was present
[29,31] at which point the replicons were concentrated by
ultracentrifugation through a 20% sucrose cushion and titered
using polyclonal antiserum against the VEE nonstructural
proteins. Expression of the truncated RVFV Gn protein from
the replicon was confirmed by western blot with a Gn specific
monoclonal antibody (RV5 3G2-1A) generously provided by Dr.
George Ludwig, USAMRIID, Ft. Detrick, Frederick, MD, USA.
In vitro expression of vaccine plasmids
The human embryonic kidney cell line, 293T, was transfected
(at 5610
5 cells/transfection) with 5mg of DNA by using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA.) according
to the manufacturer’s guidelines. Supernatants were collected and
stored at 220uC. Cell lysates were collected in 500ml of 1% Triton
X-100 buffer and stored at 220uC.
To detect specific proteins in the cell supernatant, 1.5% of
supernatant was diluted 1:2 in SDS sample buffer (Bio-Rad,
Hercules, CA, USA) and loaded onto a 10% polyacrylamide–SDS
gel. The resolved proteins were transferred onto a nitrocellulose
membrane (Bio-Rad, Hercules, CA, USA) and incubated with a
1:5,000 dilution of anti-RVFV mouse sera in phosphate-buffered
saline (PBS) containing 0.05% Tween 20 and 5% skim milk
powder. After an extensive washing, bound mouse antibodies were
detected by using a 1:5,000 dilution of horseradish peroxidase-
conjugated goat anti-mouse antiserum and enhanced chemilumi-
nescence (Amersham, Buckinghamshire, United Kingdom).
Animals and Immunizations
Six-to-eight week old female BALB/c mice (Harlan Sprague-
Dawley, Indianapolis, IN, USA) were used for inoculations. Mice,
housed with free access to food and water, were cared for under
U.S. Department of Agriculture guidelines for laboratory animals.
Mice were anesthetized with 0.03 to 0.04ml of a mixture of 5ml of
ketamine HCl (100 mg/ml) and 1ml of xylazine (20 mg/ml). Gene
gun immunizations were performed on shaved abdominal skin by
using the hand-held Bio-Rad gene delivery system as described
previously [23,32,33,34]. For DNA immunizations, mice were
immunized with three times at three week intervals with 2mgo f
DNA per 0.5mg of approximately 1-mm gold beads (Bio-Rad,
Hercules, CA, USA) at a helium pressure setting of 400 lb/in
2. For
replicon immunizations mice were given one dose at week 6 or
three doses at weeks 0, 3, and 6 of 1610
5 infectious unit (IU) of
replicons by foot pad route. Blood samples were collected at at
weeks 0, 2, 5, and 8 post-vaccination. A schematic of the vaccine
regimen is listed in Table 1. Use of animals in this study was
reviewed and approved by the University of Pittsburgh Institu-
tional Animal Care and Use Committee (IACUC).
Live attenuated and whole inactivated virus vaccines
The attenuated strain RVFV MP12 (MP12) and ZH501 was
propagated and titrated using Vero cells. A pre-titrated RVFV
MP12 was inactivated with 1% beta-propiolactone to a final
concentration of 0.1% to make a whole virus inactivated
Figure 1. RVFV DNA and replicon vaccine expression constructs and analysis of expression of RVFV Gn from them. (A). Schematic
representation of the entire polyprotein encoded my RVFV M segment (top) and the fragments (middle and bottom) cloned downstream of the tpA
leader sequence of DNA vector. (B). Schematic representation of VEE replicon plasmid encoding Gn. (C). Proteins expressed from 293T cells
transiently transfected with plasmid DNAs were assessed by SDS-PAGE and Western blot. The membrane was probed with anti-RVFV polyclonal
antibody. (D). Proteins expressed from BHK21 cells infected with packaged VEE replicons were assessed by SDS-PAGE and Western blot. The
membrane was probed with anti-RVFV polyclonal sera.
doi:10.1371/journal.pntd.0000725.g001
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aliquot of inactivated virus was used to infect Vero cells and verify
the lack of cytopathic effect (data not shown). BALB/c mice (n=5)
received a single intraperioteneal injection (i.p.) of MP12 (1610
5
PFU) 2 weeks or 8 weeks prior to infection (Table 1). Another
group of mice was administered (i.p.) 3 doses of the WIV MP12
vaccine (1610
5 PFU equivalent).
Immunological assays
Endpoint ELISA was performed on collected serum samples to
assess the anti-Gn immunoglobulin G (IgG) response. Briefly,
plates were coated with 100ml of inactivated RVFV MP12
overnight at 4uC, blocked with 5% non-fat dry milk in PBS-T
(1h) at 25uC, and then extensively washed with PBS-T. Serial
dilutions of mouse antisera were allowed to bind (1h) and the
plates thoroughly washed with PBS-T. Subsequently, the primary
antisera were detected by anti-mouse IgG conjugated to
horseradish peroxidase (Bio-Rad, Hercules, CA, USA). The
reaction was detected using tetramethybenzidine (TMB) substrate
(Sigma, Saint Louis, MO, USA) (1 h) at 25uC. IgG isotypes were
also assessed by ELISA as previously described [23,35]. The
secondary antibodies specific for IgG1, IgG2a, IgG2b and IgG3
(Southern Biotechnology, Birmingham, AL, USA) were used at
varying concentrations determined by optimization.
Neutralizing antibody assays
Antibody-mediated neutralization of RVFV ZH501 was
measured using plaque reduction and neutralization test (PRNT)
[36]. Briefly, 100 plaque-forming units (PFU)/0.1 ml of RVFV
ZH501 was mixed with serial two fold dilutions of heat inactivated
(60uC for 30 min) serum samples in 96-well tissue culture plates.
Virus-serum mixtures were incubated at 4uC overnight and placed
into duplicate 23-mm wells (0.1ml/well) containing confluent
monolayers of Vero cells (2610
5). Cells were incubated for 1h at
37uC and 5% CO2 and overlaid with nutrient medium containing
0.8% agar, 5% fetal bovine serum, 200U penicillin/ml, and
200mg streptomycin/ml. The plates were incubated at 37uC and
5% CO2. After 4 days of incubation, cells were fixed with 10%
formalin and stained with 1% crystal violet for visualization of
plaques. The neutralizing antibody titer of a serum was considered
positive at the highest initial serum dilution that inhibited .50%
of the plaques as compared to the virus control titration.
ELISPOT assays
The number of anti-Gn specific murine INF-c (mINF-c)
secreting splenocytes was determined by enzyme-linked immuno-
spot (ELISpot) assay (R & D Systems, Minneapolis, MN, USA).
Briefly, pre-coated anti-mIFN-c plates were incubated (25uC for
1h) with RPMI (200mL) supplemented with 10% fetal calf serum
and then incubated with splenocytes (5610
5/well) isolated from
vaccinated mice. Cells were stimulated (48h) with peptides (15mers
overlapping by 11 amino acids) representing the ectodomain of Gn
glycoprotein. IL-2 was added to all wells (10 units/ml). Control
wells were stimulated with PMA (+) (50 ng)/ionomycin (500 ng) or
were mock stimulated (2). Plates were washed with PBS-T (36)
and were incubated (37uC for 48h; 5% CO2) with biotinylated
anti-mIFN-c and incubated (4uC for 16h). The plates were washed
and incubated (25uC for 2h) with strepavidin conjugated to
alkaline phosphatase. Following extensive washing, cytokine/
antibody complexes were incubated (25uC for 1h) with stable
BCIP/NBT chromagen. The plates were rinsed with dH2O and
air-dried (25uC for 2h). Spots were counted by an ImmunoSpot
ELISpot reader (Cellular Technology Ltd., Cleveland, OH, USA).
RVFV ZH501 challenge
At week 8 of the study, a challenge dose containing 1610
3 PFU
of RVFV ZH501 were administered i.p. During challenge, mice
were housed in sealed negative-ventilation bio-containment units
(Allentown Inc., Allentown, NJ, USA). All manipulations with
infected mice and/or samples involving RVFV ZH501 were
performed under strict BSL-3 enhanced conditions. The animals
were examined twice daily for visual signs of morbidity or
mortality, using a lab validated scoring system as previously
described [37]. Mice were observed for clinical signs that ranged
Table 1. Vaccine groups and vaccination regimen.
Immunogens Immunization schedule Route
week 0 week 3 week 6
Gn Gn Gn Gn GG
Gn-C3d Gn-C3d Gn-C3d Gn-C3d GG
Rep-Gn Rep-Gn Rep-Gn Rep-Gn FP
Gn-C3d/Rep-Gn Gn-C3d Gn-C3d Rep-Gn GG/FP
MP12.wk0 MP12 - - IP
MP12.wk6 - - MP12 IP
WIV MP12 WIV MP12 WIV MP12 WIV MP12 IP
DNA control DNA control DNA control DNA control GG
Rep control Rep control Rep control Rep control FP
Naives - - - -
GG (gene gun), FP (foot pad) and IP (intraperitoneal).
doi:10.1371/journal.pntd.0000725.t001
Figure 2. Indirect ELISA measuring RVFV specific IgG responses
in mice immunized with indicated vaccine regimens. All groups
received primary and two booster immunizations (except MP12) spaced 3
weeks apart. Serum samples were collected two weeks after the last
immunization(week8ofthestudy),exceptforgroupofmicevaccinatedat
week 0 with MP12 (MP12.wk0) which was challenged 8 weeks post-
vaccination. End point dilution titers were conducted by diluting the sera
until the OD values reached the background levels. Eachdot representsan
individual mouse. Error bars denote the standard error within the samples
with a measurable titer. Representative data from 1 of 2 experiments
shown.A1-wayANOVAwithTukey’smultiplecomparisontestwasusedto
determine the significance of the data between groups, which is denoted
by asterisks; *** p,0.001 for both MP12 vaccine regimens compared to
the other vaccine regimens.
doi:10.1371/journal.pntd.0000725.g002
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manifestations, such as hind-limb paralysis. Mice found in a
moribund condition were euthanized.
Passive transfer of immune sera and RVFV challenge
Sera from vaccinated mice were diluted 1:10 in sterile PBS and
100ml of the diluted sera was injected (i.p.) into new, naı ¨ve BALB/
c mice. One hour following transfer, the mice were challenged
(i.p.) with virulent RVFV ZH501 (1610
3 PFU). Mice were
observed daily for 8 days post-transfer for signs of morbidity and
mortality.
Statistics
Differences in ELISA titers and virus neutralization titers
between various vaccine groups were analyzed by one-way
ANOVA, followed by Tukey’s multiple comparison test. Analysis
of results from sickness score and weight loss were assessed by two-
way ANOVA tests followed by Bonferroni’s post tests. Statistical
results are represented in the figure by * (P,0.05), ** (P,0.01), ***
(P,0.001). Statistical analyses were done using GraphPad Prism
software.
Results
Anti-Gn antibody responses
A truncated, soluble forms of Gn from the RVFV isolate
ZH548 alone or fused to three copies of murine C3d (Gn-C3d)
efficiently secreted from cells transfected with DNA plasmid and
replicon vector (Fig. 1). RVFV Gn migrated at a 45kDa
molecular weight and the C3d fusion with Gn increased the
molecular weight to 135kDa. After 3 vaccinations, mice
vaccinated with DNA plasmid expressing Gn elicited anti-Gn
antibodies (1:180), however, the fusion of C3d to Gn enhanced
the anti-Gn antibodies (1:1280), while mice vaccinated with
replicons expressing Gn (Rep-Gn) had an average anti-Gn titer of
1:2560 (Fig. 2). There were no detectable antibodies following a
single DNA vaccination (data not shown). In order to determine if
Gn-C3d-DNA could prime and enhance antibody titers following
a Rep-Gn boost, mice were vaccinated twice with Gn-C3d-DNA
and then administered a single inoculation of replicon expressing
Gn. These vaccinated mice had higher anti-Gn antibody titers
(1:4160) compared to mice vaccinated with a single vaccination of
alphavirus-replicon (1:280). Mice vaccinated the Gn-DNA only,
did not elicit any detectable anti-Gn antibodies (Fig. 3A). These
antibody responses were comparable to mice immunized with live
attenuated RVFV (MP12), but 1–2 logs lower than mice
vaccinated with three doses of whole-inactivated RVFV (WIV
MP12). MP12 infection elicited a mixed Th1 and Th2 response,
whereas mice vaccinated with three doses of WIV MP12 had a
Th2-restricted immune response (Fig. 3E and F). Mice vaccinated
with Gn-C3d-DNA vaccines elicited predominately IgG1,
suggesting a Th2 immune response (Fig. 3B and D). In contrast,
the replicons expressing Gn administered to mice three times
elicited not only IgG1, but also IgG2a and IgG2b isotypes
s u g g e s t i n gam i x e dT h 1/Th2 response similar to that elicited by
the live attenuated MP12 vaccine (Fig. 3C). Interestingly, mice
primed with Gn-C3d-DNA maintained an IgG1 isotype bias
following a boost with Gn expressing replicons (Fig. 3D). These
titers were specific to the Gn antigen, since controls (DNA
plasmid with no insert and replicons expressing the influenza
virus hemagglutinin) did not elicit anti-Gn antibodies (data not
shown).
Figure 3. Isotype ELISA measuring RVFV specific IgG isotype responses in mice with indicated vaccine regimens from week 8 sera.
1:100 dilution of serum samples from each vaccine group (A)t o( F) were used and the results are represented in OD values. Each dot represents an
individual mouse. Error bars denote the standard error within the samples with a measurable titer. Representative data from 1 of 2 experiments shown.
doi:10.1371/journal.pntd.0000725.g003
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At week 8 of the study, sera from mice vaccinated Gn-C3d-
DNA orRep-Gn neutralized (PRNT50) RVFV ZH501, while
priming mice with Gn-C3d-DNA and then boosting with Rep-Gn
did not significantly enhance the neutralizing titers compared to
Gn-C3d-DNA or Rep-Gn alone (Fig. 4). Mice vaccinated with the
live attenuated MP12 vaccine strain had the highest neutralizing
titers (average; 1:656–1:736) regardless if the mice were vaccinated
at week 0 or week 6 of the study, and they were significantly higher
than sera from mice vaccinated with Gn, Rep-Gn and WIV MP12
(p,0.05). In contrast, serum samples collected from Gn (1:22)
vaccinated or WIV MP12 (1:8) had low virus neutralizing titers in
spite of the fact that WIV MP12 elicited very high RVFV specific
antibody levels as measured by ELISA (Figure 2).
Elicitation of cellular immune responses
Mice vaccinated with DNA and replicon vaccines were
challenged with MP12 virus two weeks after last immunization
and splenocytes were collected 6 days post-infection. Cells
collected from mice vaccinated with Gn vaccines were stimulated
in vitro with 8 overlapping pools of peptide (15mers with
overlapping by 11) specific for Gn. Mice vaccinated with Rep-
Gn or Gn-C3d/Rep-Gn had responses to pools B and C (Table 2),
representing a stretch of 111 amino acids starting at amino acid 53
in the Gn sequence. Only mice vaccinated with Gn-C3d/Rep-Gn
had splenocyte responses to pool A. No responses were recorded
from any mice to pools D-G. A few spots (10–12 spots) were
detected following stimulation of splenocytes with an irrelevant
peptide or unstimulated following in vitro re-stimulation. Mice
vaccinated with DNA vaccines did not elicit cellular responses
(Table 2). In addition, no spots were detected above background
from splenocytes collected from naı ¨ve mice immunized with MP12
at day 6 post-infection (data not shown).
The peptides in these pools B and C were further analyzed to
determine the peptides responsible to eliciting these responses in
replicon-vaccinated mice. Using a matrix format, 4 out of 10 pools
(5 peptides/pool) were identified (peptide pools II, IV, VI, VII)
(Fig. 5A). From this analysis, four potential peptides (peptide # 18,
19, 36, 38) were identified as responsible for the vaccine elicited
Figure 4. Neutralizing antibody responses of mice vaccinated with indicated vaccine regimens. PRNT50 titers of week 8 sera from mice
immunized with indicated vaccines. Each dot represents an individual mouse. Error bars denote the standard error within the samples with a
measurable titer. A 1-way ANOVA with Tukey’s multiple comparison test was used to determine the significance of the data between groups, which is
denoted by asterisks; * P,0.05.
doi:10.1371/journal.pntd.0000725.g004
Table 2. Anti-Gn cell mediated immune responses of mice
vaccinated with indicated vaccine regimens.
Pools A B C D E F G H
Gn 0 0 0 0 000 0
Gn-C3d 0 0 0 0 000 0
Rep-Gn 0 541 415 0 000 0
Gn-C3d/Rep-Gn 77 301 253 0 000 0
Mock/Rep-Gn 0 171 124 0 000 0
Naive 0 0 0 0 000 0
A group of mice vaccinated with different vaccine regimens were challenged
with MP12 virus at week 8 of the study and 6 days post-infection splenocytes
were isolated and stimulated with overlapping RVFV Gn specific peptides (pools
A to H). Each pool contains 13 overlapping peptides except pool H which
contains 14. Responses are represented as average number of spots (SFU per
million cells) from different vaccine groups.
doi:10.1371/journal.pntd.0000725.t002
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amino acid sequence (SYAHHRTLL) predicted to be MHC class
I restricted (www.immuneepitope.org). A unique peptide repre-
senting this region of Gn elicited similar mINF-c cellular
immune response as the four individual peptides as indicated in
Figure 5B.
DNA and replicon vaccines protect mice against virulent
virus challenge
The mice were challenged two weeks after final vaccination with
a lethal dose (1610
3 PFU) ofRVFV ZH501. All the mice
vaccinated with an all Gn-C3d-DNA or Rep-Gn strategy or in a
DNA prime/replicon boost strategy were protected from virulent
virus challenge with no body weight loss or development of clinical
signs (Fig. 6, 7, and Table 3). Sixty percent of mice that received
Gn without the molecular adjuvant C3d displayed ruffled fur and
lethargy with one mouse succumbing to infection (Table 3 and
Fig. 6D). As expected, all the mice immunized with MP12 and
then challenged with RVFV ZH501 survived lethal challenge with
no clinical signs of infection (Table 3 and Fig. 6D). However, mice
vaccinated with WIV MP12 were not protected from challenge
with all mice exhibiting reduced body weight (Fig. 6C), ruffled fur,
lethargy (Table 3), and all mice ultimately succumbing to infection
(Fig. 6D). Unvaccinated naive mice had severe signs of infection
and body weight loss which resulted in all mice succumbing to
infection by day 4 post-challenge (Fig. 6D). Mice that received
appropriate DNA and replicon controls displayed clinical signs of
infection (Fig 7A and B) and mortality was also observed in the
control groups.
Passive sera transfer protects mice from virus infection
Pooled antiserum from each vaccinated group was transferred
(i.p.) into unimmunized mice, which were then challenged with
a lethal dose of RVFV ZH501 (Table 4). Eighty percent of mice
that received sera from MP12 immunized mice survived
challenge. A similar outcome was observed in the Gn-C3d
group where 80% of mice survived. Sera from mice primed with
Gn-C3d-DNA and then boosted with Rep-Gn or immunized
with Rep-Gn protected 40% (2/5) of mice, which was similar to
the mice that received sera from Gn-DNA vaccinated mice. All
Figure 5. Identification of the peptide sequence eliciting cellular immune response in mice vaccinated with replicons. (A). Mice
immunized with Rep-Gn vaccine were challenged with MP12 virus at week 8 of the study and 6 days post-infection splenocytes were isolated and
stimulated with overlapping RVFV Gn specific peptides representing pools B and C and peptide SYAHHRTLL. Responses are represented as average
number of spots (SFU per million cells). The highlighted peptides 18 and 19 share a common amino acid sequence SYAHHRTLL. Representative data
from 1 of 2 experiments shown. (B). Schematic alignment of identified peptides with Gn. Numbers in the parentheses represent amino acid positions
of the individual peptide. The gray box indicates the region of Gn covered by the predicted CD8+ T cells epitope SYAHHRTLL.
doi:10.1371/journal.pntd.0000725.g005
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or mice that received sera from control immunized mice (DNA
control, Rep control, Naı ¨ve) succumbed to virulent RVFV
ZH501 infection.
Discussion
One of the goals of an effective RVFV vaccine is to elicit
protective neutralizing antibodies. In recent years, several RVFV
vaccines strategies have been employed to elicit a potent
neutralizing antibody responses [36,38,39,40,41,42,43], however,
these vaccines did not always elicit high titer immune responses
that protected against lethal challenge. In addition, several of these
innovative strategies may not be appropriate for human use. Early
RVFV vaccine studies focused on live-attenuated and inactivated
virus strategies that induce long-lasting protection [36,44,45].
However, the induction of adverse reactions may likely limit the
wide spread use of live-attenuated vaccines [15,16,18]. In contrast,
inactivated virus vaccines often require multiple immunizations to
elicit protective immune responses [46] and there is concern that
the immunity elicited by these vaccines may rapidly wane without
frequent booster vaccinations. In addition to potential concerns
about safety or efficacy, due to the bioterrorism potential, ability to
create virgin soil epidemics and zoonotic importance of RVFV,
sero-surveillance is of major importance in the international trade
of animals and animal-related products. Marker vaccines make it
possible to differentiate infected from vaccinated animals [47].
Diagnostic tests such as RVFV recombinant N protein based
ELISA and immuno-fluorescence performed on infected or
transfected cells or tissues are widely used in laboratories for
RVFV diagnosis [48,49,50,51]. Therefore, an ideal vaccine,
especially for livestock applications, would lack the RVFV N
protein, which would allow differentiation between vaccinated and
infected individuals.
To overcome the limitations discussed above, we have
developed two promising vaccine candidates based on DNA
plasmid and alphavirus replicon vectors that express the virus
envelope glycoprotein, Gn. Each vaccine was tested alone or in
a DNA prime/replicon boost strategy formulation to elicit
protective immune response against virulent RVFV infection in
mice. DNA vaccines have been licensed for veterinary use [52].
However, DNA vaccines have been less effective in human
clinical trials for other infectious diseases [52,53]. In order to
enhance the antibody responses elicited by DNA vaccines, our
laboratory has pioneered the use of the complement protein
C3d as a molecular adjuvant [20,23,25]. Since the Gn
Figure 6. Weight loss curves and survival against virulent RVFV challenge of mice vaccinated with indicated vaccine regimens. Mice
vaccinated with indicated vaccines or appropriate controls, DNA plasmid with no insert (DNA control) and replicon expressing influenza HA (replicon
control) were challenged with 1000 PFU of RVFV ZH501 and monitored for loss in body weight (A)t o( C) and mortality (D) daily post-challenge. Dead
and moribund mice were included in the weight loss curves on the day of death, but not after. The daily weight of each mouse was compared to her
weight on the day of challenge, and data are shown as the average percentage of initial weight for each cohort. Error bars represent the standard
error for all samples available at that time point. A two-way ANOVA with Bonferroni’s post tests was used to determine the significance of the body
weight data between groups, which is denoted by asterisks; *P,0.05, **P,0.01, *** P,0.001. All vaccinated mice showed statistically significant
protection (P,0.05, log rank test) compared to unvaccinated mice.
doi:10.1371/journal.pntd.0000725.g006
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epitopes [38,40,42,54], we focused our efforts on characterizing
whether fusion of the C3d molecule to Gn resulted in enhanced
RVFV specific immunity. Mice vaccinated with Gn-C3d-DNA
had high titer neutralizing antibodies compared to mice
vaccinated with DNA expressing Gn alone. It remains to be
determined whether this effect is solely due to C3d’s function as
a molecular adjuvant or whether the fusion of C3d also
Figure 7. Post-challenge sickness score in mice vaccinated with indicated vaccine regimens. Mice immunized with indicated vaccines or
appropriate controls, DNA plasmid with no insert (DNA control) and replicon expressing influenza HA (replicon control) (A) to (C) were challenged
with 1000 PFU of RVFV ZH501 and monitored for clinical signs associated with RVFV infection and mortality daily post-challenge. (D) Mice were
evaluated daily and scored for individual symptoms. Ruffled fur (absent=0, present=1), activity (normal=0, reduced=1), hunched (absent=0,
present=1). The final score was the addition of each individual score. The minimum score was 0 for healthy and 1–3 depending upon the severity. A
two-way ANOVA with Bonferroni’s post tests was used to determine the significance of sickness score data between different groups, which is
denoted by asterisks; **P,0.01, *** P,0.001.
doi:10.1371/journal.pntd.0000725.g007
Table 3. Clinical profile of mice vaccinated with indicated vaccines or controls.
GROUPS RUFFLED FUR LETHARGY HUNCHED PARALYTIC SIGNS Hemorrhage DEAD/EUTHANIZED
Gn 3/5 3/5 0/5 0/5 0/5 1/5
Gn-C3d 0/5 0/5 0/5 0/5 0/5 0/5
Rep-Gn 0/5 0/5 0/5 0/5 0/5 0/5
Rep-Gn.wk6 5/5 5/5 1/5 0/5 0/5 3/5
DNA-C3d/Rep-Gn 0/5 0/5 0/5 0/5 0/5 0/5
MP12.wk0 0/5 0/5 0/5 0/5 0/5 0/5
MP12.wk6 0/5 0/5 0/5 0/5 0/5 0/5
WIV MP12 4/5 4/5 1/5 1/5 0/5 5/5
DNA control 5/5 5/5 0/5 0/5 0/5 2/5
Rep control 5/5 5/5 0/5 1/5 0/5 4/5
Mock vaccinated 5/5 5/5 0/5 0/5 0/5 5/5
Numbers in the parentheses indicate the number of immunizations performed for each vaccine or control.
doi:10.1371/journal.pntd.0000725.t003
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stability in the extracellular environment.
In addition to the DNA vaccine strategy, we also used a DNA
prime/alphavirus replicon boost strategy to expand the repertoire
of elicited immune responses. Previously, our group used a Sindbis
virus replicon vectors expressing the RVFV Gn and Gc
glycoproteins, as well as the non-structural NsM protein to induce
protective immune responses in mice against RVFV [29]. In this
study, the replicons administered alone or in a DNA prime/
replicon boost strategy elicited similar anti-Gn antibody titers,
however, different subclasses of IgG were elicited by each vaccine.
The isotype of the polyclonal antibody in part determines the
effector functions of the anti-Gn antibodies and identifies the T
helper cell bias (required for antibody class switching). The
predominant isotype elicited by DNA and replicon immunizations
was IgG1 indicating a Th2 bias. Antibodies of the IgG2a/c and
IgG2b subclass fix complement proteins C1q and C3 and can
opsonize and inhibit infection. IgG2a/c binds FccRI with high
avidity facilitating enhanced uptake of virus-antibody complexes
by macrophages. The predominant IgG isotype elicited by DNA
vaccination was IgG1 indicating a Th2 bias. However, IgG1,
IgG2a, and IgG2b were detected in both replicon vaccinated, as
well as live MP12 immunized mice (Fig. 3), indicating that both
the replicon and the live attenuated vaccine elicit a mixed T-
helper response.
Even though both MP12 infection and the WIV vaccination
elicited the highest anti-Gn titers, only the live MP12 infection
elicited strong neutralizing antibody responses (Fig. 4). Gn-C3d-
DNA and Gn-C3d-DNA/Rep-Gn vaccinated mice had statisti-
cally similar neutralizing titers as MP12 immunized mice. Studies
in the past have mainly focused on survival of vaccinated mice
post-challenge; however an ideal vaccine should not only be able
to protect from virus infection, but also prevent development of
clinical symptoms. In this study, we evaluated our candidate
vaccines for the ability to confer protection, as well as ability to
prevent clinical signs. Few mice from DNA and replicon control
groups survived virus infection similar to previous studies [38,39],
however all of the control mice displayed clinical signs of infection
that was characterized by ruffled fur and lethargy. We observed a
correlation between neutralizing antibody titers and development
of clinical signs or mortality. Mice with a PRNT50 value of ,1:10
succumbed to lethal infection and a PRNT50 value of $1:40 was
sufficient to prevent clinical signs. This indicates that the clinical
sickness score more accurately reflected vaccine efficacy in
preventing RVFV infection and may be a useful tool for future
vaccine studies.
The issue of survival from control DNA or mock vaccination is
curious, but has been observed in previous publications. Spik et al.
[39] also saw survival of a subset of mice following vaccination
with DNA controls up to 31 days following challenge with Rift
Valley fever virus. In addition, Bird et al. observed that sham mice
did not succumb to lethal Rift Valley fever virus challenge, but
they developed severe clinical signs of ruffled fur, hunched back,
and lethargy [48].
To further explore the ability of factors in the sera to protection
mice from RVFV infection, passive transfer of serum from
vaccinated mice to naı ¨ve mice demonstrated that humoral
immune response play a major role in anti-RVFV immunity
(Table 4) [40]. Not all mice passively administered the serum were
protected, which may be due to dilution of the neutralizing
antibodies during preparation that resulted in lack of protection in
some mice. Mice vaccinated with replicons alone or in a DNA
prime/replicon boost strategy, but not by DNA alone, had robust
cellular responses directed at Gn. Cellular responses are critical for
clearing virally infected cells in many systems. Although the
elicitation of robust neutralizing antibodies are considered ideal for
the development of an effective RVFV vaccine, induction of
cellular responses by immunization may clear virally infected cells,
reduce morbidity, and hasten recovery from infection. The
replicon-based vaccines elicited cellular immune responses against
the Gn protein, but Gn expressed from DNA plasmids did not,
even though priming mice with DNA did not dampen the
induction of cellular responses by the Gn-C3d/Rep-Gn in the
DNA prime/replicon boost regimen (Table 2). Although non-
specific induction of T-cell responses against RVFV glycoproteins
and nucleocapsid proteins have been previously reported [55], this
is the first report to identify an MHC-I restricted immunodomi-
nant epitope (SYAHHRTLL) on the surface of Gn as predicted by
mutlitple algorithm methods to detect the peptide sequence with
lowest IC50 and hence better binding to MHC-I [www.
immuneepitope.org]. Although, both Rep-Gn alone or in a
DNA prime/replicon boost approach Gn-C3d/Rep-Gn induced
a combination of humoral and cell mediated immune responses
and therefore this strategy may warrant further evaluation in large
animals and humans.
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Table 4. Passive transfer of sera from vaccinated mice
protects against lethal RVFV challenge.
Vaccine Groups Survivors
Gn 3/5
Gn-C3d 4/5
Rep-Gn 2/5
Gn-C3d/Rep-Gn 2/5
MP12.wk0 4/5
MP12.wk6 5/5
WIV MP12 0/5
DNA Control 0/5
Rep Control 0/5
Naive 0/5
Mock challenged 5/5
Five to six weeks old BALB/c mice were pre-treated with 100 ml of 1:10 diluted
serum from the indicated vaccinated mice or naı ¨ve animals by intraperitoneal
injection. One hour post-sera inoculation mice were infected with 1000 PFU of
RVFV by intraperitoneal route and monitored for survival.
doi:10.1371/journal.pntd.0000725.t004
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